Business Wire

Phasecraft Joins DARPA’s Quantum Benchmarking Initiative

3.3.2026 16:49:00 CET | Business Wire | Press Release

Share

Phasecraft, the world’s leading quantum algorithms company, today announced it has commenced work on the University of Maryland’s Applied Research Laboratory for Intelligence and Security’s (ARLIS) new contract to support the Defense Advanced Research Projects Agency’s (DARPA) ongoing Quantum Benchmarking Initiative (QBI). QBI’s goal is to assess if it is possible to achieve utility-scale quantum computing by 2033. Phasecraft joins the contract as a technical expert and will leverage its proprietary software and quantum algorithms to develop optimized estimates of resource requirements for quantum applications to inform the U.S. Government (USG) verification and validation efforts.

Evaluating Progress Towards Quantum Utility

While the cutting-edge quantum hardware selected for QBI inches closer to commercial utility, ultra-efficient quantum algorithms like those Phasecraft develops are required to unlock the full potential of any quantum hardware. The company’s hardware-agnostic algorithms, which in some cases are millions of times more efficient than the best previous work, enable the company to provide unique value to ARLIS, DARPA, and the USG.

Specifically, Phasecraft’s work will focus on two application areas: 1) materials and molecular modeling; and 2) hard optimization problems. In both cases, Phasecraft’s algorithms have pushed the boundaries of what was thought possible, and radically shortened the timeline to quantum advantage – the point at which quantum computers will outperform classical methods. This enables the company to produce far more accurate estimates of when quantum will deliver true utility to users across application areas.

“The team at DARPA has long understood the strategic importance of quantum computing and we are thrilled at the opportunity to collaborate on this vital work, working alongside ARLIS,” saidAshley Montanaro, co-founder and CEO of Phasecraft. “For all the emphasis we see on hardware in the field, it is gratifying to have a government partner like DARPA appreciate the importance of quantum algorithms in the race to achieve industrially useful quantum computing. Our quantum algorithms are delivering meaningful results today, and we’re excited to join the impressive QBI team.”

Building on Momentum

A preferred research partner for all the leading hardware companies like Google Quantum AI, IBM, Quantinuum and QuEra, Phasecraft prioritizes making quantum useful in the near term. InOctober, Phasecraft unveiled Mondrian, its first-of-a-kind quantum-enhanced software platform designed to speed up classical optimization algorithms and apply them to hard optimization and constraint satisfaction problems across several industries. Mondrian demonstrates how classical and quantum computing can work together to tackle some of the most complex optimization problems facing industries such as energy, finance, and logistics.

This contract comes on the heels of the company’s recent $34M Series B fundraising announcement. The new funding brings the total raised to over $50M – including grant and contract funding – and will allow the company to double down on its R&D breakthroughs and expand industrial efforts, building real-world solutions for end users.

About Phasecraft

Phasecraft is the UK and U.S-based quantum algorithms company whose mission is to accelerate the practical application of quantum computing by redesigning quantum algorithms for the imperfect quantum computers of today. Phasecraft was founded in 2019 by Toby Cubitt, Ashley Montanaro, and John Morton, expert quantum scientists who have spent decades leading top research teams at UCL and the University of Bristol. Phasecraft works in partnership with leading quantum hardware companies, including Google, IBM, Quantinuum, and QuEra, academic and industry leaders, to develop high-efficiency algorithms to move quantum computing from experimental demonstrations to useful applications. Learn more: www.phasecraft.io

View source version on businesswire.com: https://www.businesswire.com/news/home/20260303517174/en/

Contacts

Meredith Bell
+447451298769
meredith@phasecraft.io

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press Release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press Release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press Release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye